BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 30,621 Shares of Illumina, Inc. $ILMN

BNP PARIBAS ASSET MANAGEMENT Holding S.A. decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 32.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 63,186 shares of the life sciences company’s stock after selling 30,621 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Illumina were worth $6,001,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Empowered Funds LLC grew its holdings in Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC bought a new position in shares of Illumina during the 2nd quarter worth about $621,000. Nordea Investment Management AB grew its stake in shares of Illumina by 14.2% in the 2nd quarter. Nordea Investment Management AB now owns 13,138 shares of the life sciences company’s stock valued at $1,265,000 after buying an additional 1,633 shares during the period. Chicago Partners Investment Group LLC increased its position in Illumina by 85.6% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 5,200 shares of the life sciences company’s stock valued at $544,000 after buying an additional 2,398 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale increased its position in Illumina by 0.3% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 102,344 shares of the life sciences company’s stock valued at $9,617,000 after buying an additional 295 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Insider Transactions at Illumina

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares in the company, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the transaction, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. The trade was a 1.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.60% of the company’s stock.

Illumina Trading Down 0.1%

NASDAQ:ILMN opened at $120.00 on Friday. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $155.53. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. The firm’s 50 day moving average is $136.15 and its 200 day moving average is $116.94. The stock has a market capitalization of $18.35 billion, a PE ratio of 22.02, a price-to-earnings-growth ratio of 2.30 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period last year, the business posted $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ILMN shares. Guggenheim upped their price objective on shares of Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Wall Street Zen raised shares of Illumina from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 14th. Robert W. Baird set a $137.00 target price on shares of Illumina in a report on Friday, February 6th. Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Finally, Stifel Nicolaus boosted their price objective on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Six analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Illumina has an average rating of “Hold” and an average target price of $127.94.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.